



Effective Date:
Monday, April 03, 2017

Test Updates

In our continuing effort to provide you with the highest quality toxicology laboratory services available, we have compiled important changes regarding a number of tests we perform. Listed below are the types of changes that may be included in this notification, effective Monday, April 03, 2017

Test Changes - Tests that have had changes to the method/ CPT code, units of measurement, scope of analysis, reference comments, or specimen requirements.

Discontinued Tests - Tests being discontinued with alternate testing suggestions.

Please use this information to update your computer systems/records. These changes are important to ensure standardization of our mutual laboratory databases.

If you have any questions about the information contained in this notification, please call our Client Support Department at (866) 522-2206. Thank you for your continued support of NMS Labs and your assistance in implementing these changes.

The CPT Codes provided in this document are based on AMA guidelines and are for informational purposes only. NMS Labs does not assume responsibility for billing errors due to reliance on the CPT Codes listed in this document.



Effective Date:
Monday, April 03, 2017

Test Updates

Test Code	Test Name	Test Name	Method / CPT Code	Specimen Req.	Stability	Scope	Units	Reference Comments	Discontinue
0165B	Albuterol, Blood							•	
0165SP	Albuterol, Serum/Plasma							•	
1485B	Designer Opioids, Blood				•				
1485SP	Designer Opioids, Serum/Plasma				•				
1450SP	Drug-Facilitated Sexual Assault Screen, Serum/Plasma (Forensic)							•	
1452B	Drug-Facilitated Sexual Assault Survey 2, Blood (Forensic)							•	
5101B	Gamma-Hydroxybutyric Acid Confirmation, Blood							•	
52163B	Gamma-Hydroxybutyric Acid Confirmation, Blood (Forensic) (CSA)							•	
5101FL	Gamma-Hydroxybutyric Acid Confirmation, Fluid							•	
52163FL	Gamma-Hydroxybutyric Acid Confirmation, Fluid (Forensic) (CSA)							•	
5101SP	Gamma-Hydroxybutyric Acid Confirmation, Serum/Plasma							•	
52163SP	Gamma-Hydroxybutyric Acid Confirmation, Serum/Plasma (Forensic) (CSA)							•	
5101TI	Gamma-Hydroxybutyric Acid Confirmation, Tissue							•	
52163TI	Gamma-Hydroxybutyric Acid Confirmation, Tissue (Forensic) (CSA)							•	
9553B	Gamma-Hydroxybutyric Acid Screen (Add-On), Blood (Forensic) (CSA)							•	
9553FL	Gamma-Hydroxybutyric Acid Screen (Add-On), Fluid (Forensic) (CSA)							•	
9553SP	Gamma-Hydroxybutyric Acid Screen (Add-On), Serum/Plasma (Forensic) (CSA)							•	
9553TI	Gamma-Hydroxybutyric Acid Screen (Add-On), Tissue (Forensic) (CSA)							•	
9326B	Gamma-Hydroxybutyric Acid Screen, Blood							•	
9326FL	Gamma-Hydroxybutyric Acid Screen, Fluid							•	
9326SP	Gamma-Hydroxybutyric Acid Screen, Serum/Plasma							•	
9326TI	Gamma-Hydroxybutyric Acid Screen, Tissue							•	
2435B	Isocarboxazid (as Benzylhydrazine), Blood								•
2532SP	Leflunomide as Metabolite (Pre-Pregnancy Monitoring), Serum/Plasma				•				
2531SP	Leflunomide as Metabolite (Therapeutic Drug Monitoring), Serum/Plasma				•				
10009SP	Low Leflunomide Metabolite, Serum/Plasma (CSA)				•				



Effective Date:
Monday, April 03, 2017

Test Updates

Test Code	Test Name	Test Name	Method / CPT Code	Specimen Req.	Stability	Scope	Units	Reference Comments	Discontinue
2576B	MCPA Herbicide, Blood								•
2576SP	MCPA Herbicide, Serum/Plasma								•
2576U	MCPA Herbicide, Urine								•
3995B	R-410A (Puron®), Blood								•
4367SP	Teriflunomide (Pre-Pregnancy Monitoring), Serum/Plasma				•				
4366SP	Teriflunomide (Therapeutic Drug Monitoring), Serum/Plasma				•				
4652U	Trichloropyridinol-3,5,6, Urine								•



Effective Date:
Monday, April 03, 2017

Test Updates

Test Changes

0165B Albuterol, Blood

Summary of Changes: Reference Comment was changed.

Scope of Analysis: LC-MS/MS (80375): Albuterol
Method (CPT Code)

Compound Name	Units	Reference Comment
Albuterol	ng/mL	Peak plasma levels following a 180 mcg dose via an inhaler: 1.5 ng/mL at 13 minutes post dose. Peak plasma levels following inhalation of a cumulative dose of 1 mg and 4 mg: approximately 5 and 20 ng/mL, respectively, 5 minutes post dose. Peak plasma levels following a single 8 mg oral-sustained release tablet: 13 ng/mL at 5.0 hours post dose. Average steady-state peak and trough plasma levels following a 4 mg (normal release tablet) every 6 hours for 5 days: 15 and 9.9 ng/mL, respectively. Blood concentrations may vary significantly depending on dose, formulation, route of administration, device, lung function, and user mechanics. The blood to plasma ratio is 1.0 for albuterol.

0165SP Albuterol, Serum/Plasma

Summary of Changes: Reference Comment was changed.

Scope of Analysis: LC-MS/MS (80375): Albuterol
Method (CPT Code)

Compound Name	Units	Reference Comment
Albuterol	ng/mL	Peak plasma levels following a 180 mcg dose via an inhaler: 1.5 ng/mL at 13 minutes post dose. Peak plasma levels following inhalation of a cumulative dose of 1 mg and 4 mg: approximately 5 and 20 ng/mL, respectively, 5 minutes post dose. Peak plasma levels following a single 8 mg oral-sustained release tablet: 13 ng/mL at 5.0 hours post dose. Average steady-state peak and trough plasma levels following a 4 mg (normal release tablet) every 6 hours for 5 days: 15 and 9.9 ng/mL, respectively. Serum/plasma concentrations may vary significantly depending on dose, formulation, route of administration, device, lung function, and user mechanics.

1485B Designer Opioids, Blood



Test Updates

Test Changes

Summary of Changes: Stability was changed.

Stability: Room Temperature: 14 day(s)
Refrigerated: 30 day(s)
Frozen (-20 °C): 30 day(s)

1485SP Designer Opioids, Serum/Plasma

Summary of Changes: Stability was changed.

Stability: Room Temperature: 7 day(s)
Refrigerated: 30 day(s)
Frozen (-20 °C): 30 day(s)

1450SP Drug-Facilitated Sexual Assault Screen, Serum/Plasma (Forensic)

Summary of Changes: Reference Comment was changed.

Scope of Analysis:
Method (CPT Code)

Compound Name	Units	Reference Comment
Gamma-Hydroxybutyric Acid	mcg/mL	<p>Following an oral dose of 4.5 g, peak plasma concentrations averaged 90 mcg/mL approximately 50 minutes after administration. GHB has a terminal half-life of 0.5 to 1 hour.</p> <p>The following effects have been generally associated with the corresponding blood concentrations: >260 mcg/mL: Deep sleep/coma 150 - 260 mcg/mL: Moderate sleep 52 - 150 mcg/mL: Light sleep < 52 mcg/mL: Wakefulness Responses are variable and may differ even within the same individual. The value reported for GHB is a total of GHB and its lactone (GBL) in the specimen.</p>

1452B Drug-Facilitated Sexual Assault Survey 2, Blood (Forensic)

Summary of Changes: Reference Comment was changed.

Scope of Analysis:
Method (CPT Code)



Effective Date:
Monday, April 03, 2017

Test Updates

Test Changes

Compound Name	Units	Reference Comment
Gamma-Hydroxybutyric Acid	mcg/mL	<p>Following an oral dose of 4.5 g, peak plasma concentrations averaged 90 mcg/mL approximately 50 minutes after administration. GHB has a terminal half-life of 0.5 to 1 hour.</p> <p>The following effects have been generally associated with the corresponding blood concentrations: >260 mcg/mL: Deep sleep/coma 150 - 260 mcg/mL: Moderate sleep 52 - 150 mcg/mL: Light sleep < 52 mcg/mL: Wakefulness Responses are variable and may differ even within the same individual. The value reported for GHB is a total of GHB and its lactone (GBL) in the specimen.</p>

52163B Gamma-Hydroxybutyric Acid Confirmation, Blood (Forensic) (CSA)

Summary of Changes: Reference Comment was changed.

Scope of Analysis: GC/MS (83921): Gamma-Hydroxybutyric Acid
Method (CPT Code)

Compound Name	Units	Reference Comment
Gamma-Hydroxybutyric Acid	mcg/mL	<p>Following an oral dose of 4.5 g, peak plasma concentrations averaged 90 mcg/mL approximately 50 minutes after administration. GHB has a terminal half-life of 0.5 to 1 hour.</p> <p>The following effects have been generally associated with the corresponding blood concentrations: >260 mcg/mL: Deep sleep/coma 150 - 260 mcg/mL: Moderate sleep 52 - 150 mcg/mL: Light sleep < 52 mcg/mL: Wakefulness Responses are variable and may differ even within the same individual. The value reported for GHB is a total of GHB and its lactone (GBL) in the specimen.</p>

5101B Gamma-Hydroxybutyric Acid Confirmation, Blood

Summary of Changes: Reference Comment was changed.



Test Updates

Test Changes

Scope of Analysis: GC/MS (83921): Gamma-Hydroxybutyric Acid
Method (CPT Code)

Compound Name	Units	Reference Comment
Gamma-Hydroxybutyric Acid	mcg/mL	<p>Following an oral dose of 4.5 g, peak plasma concentrations averaged 90 mcg/mL approximately 50 minutes after administration. GHB has a terminal half-life of 0.5 to 1 hour.</p> <p>The following effects have been generally associated with the corresponding blood concentrations: >260 mcg/mL: Deep sleep/coma 150 - 260 mcg/mL: Moderate sleep 52 - 150 mcg/mL: Light sleep < 52 mcg/mL: Wakefulness Responses are variable and may differ even within the same individual. The value reported for GHB is a total of GHB and its lactone (GBL) in the specimen.</p>

52163FL Gamma-Hydroxybutyric Acid Confirmation, Fluid (Forensic) (CSA)

Summary of Changes: Reference Comment was changed.

Scope of Analysis: GC/MS (83921): Gamma-Hydroxybutyric Acid
Method (CPT Code)

Compound Name	Units	Reference Comment
Gamma-Hydroxybutyric Acid	mcg/mL	No reference data available. The value reported for GHB is a total of GHB and its lactone (GBL) in the specimen.

5101FL Gamma-Hydroxybutyric Acid Confirmation, Fluid

Summary of Changes: Reference Comment was changed.

Scope of Analysis: GC/MS (83921): Gamma-Hydroxybutyric Acid
Method (CPT Code)

Compound Name	Units	Reference Comment
Gamma-Hydroxybutyric Acid	mcg/mL	No reference data available. The value reported for GHB is a total of GHB and its lactone (GBL) in the specimen.

52163SP Gamma-Hydroxybutyric Acid Confirmation, Serum/Plasma (Forensic) (CSA)

Summary of Changes: Reference Comment was changed.



Effective Date:
Monday, April 03, 2017

Test Updates

Test Changes

Scope of Analysis: GC/MS (83921): Gamma-Hydroxybutyric Acid
Method (CPT Code)

Compound Name	Units	Reference Comment
Gamma-Hydroxybutyric Acid	mcg/mL	<p>Following an oral dose of 4.5 g, peak plasma concentrations averaged 90 mcg/mL approximately 50 minutes after administration. GHB has a terminal half-life of 0.5 to 1 hour.</p> <p>The following effects have been generally associated with the corresponding blood concentrations: >260 mcg/mL: Deep sleep/coma 150 - 260 mcg/mL: Moderate sleep 52 - 150 mcg/mL: Light sleep < 52 mcg/mL: Wakefulness Responses are variable and may differ even within the same individual. The value reported for GHB is a total of GHB and its lactone (GBL) in the specimen.</p>

5101SP Gamma-Hydroxybutyric Acid Confirmation, Serum/Plasma

Summary of Changes: Reference Comment was changed.

Scope of Analysis: GC/MS (83921): Gamma-Hydroxybutyric Acid
Method (CPT Code)

52163TI Gamma-Hydroxybutyric Acid Confirmation, Tissue (Forensic) (CSA)

Summary of Changes: Reference Comment was changed.

Scope of Analysis: GC/MS (83921): Gamma-Hydroxybutyric Acid
Method (CPT Code)

Compound Name	Units	Reference Comment
Gamma-Hydroxybutyric Acid	mcg/g	No reference data available. The value reported for GHB is a total of GHB and its lactone (GBL) in the specimen.

5101TI Gamma-Hydroxybutyric Acid Confirmation, Tissue

Summary of Changes: Reference Comment was changed.

Scope of Analysis: GC/MS (83921): Gamma-Hydroxybutyric Acid
Method (CPT Code)



Effective Date:
Monday, April 03, 2017

Test Updates

Test Changes

Compound Name	Units	Reference Comment
Gamma-Hydroxybutyric Acid	mcg/g	No reference data available. The value reported for GHB is a total of GHB and its lactone (GBL) in the specimen.

9553B Gamma-Hydroxybutyric Acid Screen (Add-On), Blood (Forensic) (CSA)

Summary of Changes: Reference Comment was changed.

Scope of Analysis: GC/MS (80307): Gamma-Hydroxybutyric Acid
Method (CPT Code)

Compound Name	Units	Reference Comment
Gamma-Hydroxybutyric Acid	mcg/mL	<p>Following an oral dose of 4.5 g, peak plasma concentrations averaged 90 mcg/mL approximately 50 minutes after administration. GHB has a terminal half-life of 0.5 to 1 hour.</p> <p>The following effects have been generally associated with the corresponding blood concentrations: >260 mcg/mL: Deep sleep/coma 150 - 260 mcg/mL: Moderate sleep 52 - 150 mcg/mL: Light sleep < 52 mcg/mL: Wakefulness Responses are variable and may differ even within the same individual. The value reported for GHB is a total of GHB and its lactone (GBL) in the specimen.</p>

9553FL Gamma-Hydroxybutyric Acid Screen (Add-On), Fluid (Forensic) (CSA)

Summary of Changes: Reference Comment was changed.

Scope of Analysis: GC/MS (80307): Gamma-Hydroxybutyric Acid
Method (CPT Code)

Compound Name	Units	Reference Comment
Gamma-Hydroxybutyric Acid	mcg/mL	No reference data available. The value reported for GHB is a total of GHB and its lactone (GBL) in the specimen.

9553SP Gamma-Hydroxybutyric Acid Screen (Add-On), Serum/Plasma (Forensic) (CSA)

Summary of Changes: Reference Comment was changed.

Scope of Analysis: GC/MS (80307): Gamma-Hydroxybutyric Acid
Method (CPT Code)



Effective Date:
Monday, April 03, 2017

Test Updates

Test Changes

Compound Name	Units	Reference Comment
Gamma-Hydroxybutyric Acid	mcg/mL	<p>Following an oral dose of 4.5 g, peak plasma concentrations averaged 90 mcg/mL approximately 50 minutes after administration. GHB has a terminal half-life of 0.5 to 1 hour.</p> <p>The following effects have been generally associated with the corresponding blood concentrations: >260 mcg/mL: Deep sleep/coma 150 - 260 mcg/mL: Moderate sleep 52 - 150 mcg/mL: Light sleep < 52 mcg/mL: Wakefulness Responses are variable and may differ even within the same individual. The value reported for GHB is a total of GHB and its lactone (GBL) in the specimen.</p>

9553TI Gamma-Hydroxybutyric Acid Screen (Add-On), Tissue (Forensic) (CSA)

Summary of Changes: Reference Comment was changed.

Scope of Analysis: GC/MS (80307): Gamma-Hydroxybutyric Acid
Method (CPT Code)

Compound Name	Units	Reference Comment
Gamma-Hydroxybutyric Acid	mcg/g	No reference data available. The value reported for GHB is a total of GHB and its lactone (GBL) in the specimen.

9326B Gamma-Hydroxybutyric Acid Screen, Blood

Summary of Changes: Reference Comment was changed.

Scope of Analysis: GC/MS (80307): Gamma-Hydroxybutyric Acid
Method (CPT Code)

Compound Name	Units	Reference Comment
Gamma-Hydroxybutyric Acid	mcg/mL	<p>Following an oral dose of 4.5 g, peak plasma concentrations averaged 90 mcg/mL approximately 50 minutes after administration. GHB has a terminal half-life of 0.5 to 1 hour.</p> <p>The following effects have been generally associated with the corresponding blood concentrations: >260 mcg/mL: Deep sleep/coma 150 - 260 mcg/mL: Moderate sleep</p>



Test Updates

Test Changes

Compound Name	Units	Reference Comment
		52 - 150 mcg/mL: Light sleep < 52 mcg/mL: Wakefulness Responses are variable and may differ even within the same individual. The value reported for GHB is a total of GHB and its lactone (GBL) in the specimen.

9326FL Gamma-Hydroxybutyric Acid Screen, Fluid

Summary of Changes: Reference Comment was changed.

Scope of Analysis: GC/MS (80307): Gamma-Hydroxybutyric Acid
Method (CPT Code)

Compound Name	Units	Reference Comment
Gamma-Hydroxybutyric Acid	mcg/mL	No reference data available. The value reported for GHB is a total of GHB and its lactone (GBL) in the specimen.

9326SP Gamma-Hydroxybutyric Acid Screen, Serum/Plasma

Summary of Changes: Reference Comment was changed.

Scope of Analysis: GC/MS (80307): Gamma-Hydroxybutyric Acid
Method (CPT Code)

Compound Name	Units	Reference Comment
Gamma-Hydroxybutyric Acid	mcg/mL	Following an oral dose of 4.5 g, peak plasma concentrations averaged 90 mcg/mL approximately 50 minutes after administration. GHB has a terminal half-life of 0.5 to 1 hour. The following effects have been generally associated with the corresponding blood concentrations: >260 mcg/mL: Deep sleep/coma 150 - 260 mcg/mL: Moderate sleep 52 - 150 mcg/mL: Light sleep < 52 mcg/mL: Wakefulness Responses are variable and may differ even within the same individual. The value reported for GHB is a total of GHB and its lactone (GBL) in the specimen.

9326TI Gamma-Hydroxybutyric Acid Screen, Tissue



Test Updates

Test Changes

Summary of Changes: Reference Comment was changed.

Scope of Analysis: GC/MS (80307): Gamma-Hydroxybutyric Acid
Method (CPT Code)

Compound Name	Units	Reference Comment
Gamma-Hydroxybutyric Acid	mcg/g	No reference data available. The value reported for GHB is a total of GHB and its lactone (GBL) in the specimen.

2532SP Leflunomide as Metabolite (Pre-Pregnancy Monitoring), Serum/Plasma

Summary of Changes: Stability was changed.

Stability: Room Temperature: 30 day(s)
Refrigerated: 30 day(s)
Frozen (-20 °C): 10 month(s)

2531SP Leflunomide as Metabolite (Therapeutic Drug Monitoring), Serum/Plasma

Summary of Changes: Stability was changed.

Stability: Room Temperature: 30 day(s)
Refrigerated: 30 day(s)
Frozen (-20 °C): 10 month(s)

10009SP Low Leflunomide Metabolite, Serum/Plasma (CSA)

Summary of Changes: Stability was changed.

Stability: Room Temperature: 30 day(s)
Refrigerated: 30 day(s)
Frozen (-20 °C): 10 month(s)

4367SP Teriflunomide (Pre-Pregnancy Monitoring), Serum/Plasma

Summary of Changes: Stability was changed.

Stability: Room Temperature: 30 day(s)
Refrigerated: 30 day(s)
Frozen (-20 °C): 10 month(s)

4366SP Teriflunomide (Therapeutic Drug Monitoring), Serum/Plasma

Summary of Changes: Stability was changed.

Stability: Room Temperature: 30 day(s)
Refrigerated: 30 day(s)
Frozen (-20 °C): 10 month(s)



Effective Date:
Monday, April 03, 2017

Test Updates

Discontinued Tests

Test Code	Test Name	Alternative Test
2435B	Isocarboxazid (as Benzylhydrazine), Blood	No Alternate Tests Available
2576B	MCPA Herbicide, Blood	No Alternate Tests Available
2576SP	MCPA Herbicide, Serum/Plasma	No Alternate Tests Available
2576U	MCPA Herbicide, Urine	No Alternate Tests Available
3995B	R-410A (Puron®), Blood	No Alternate Tests Available
4652U	Trichloropyridinol-3,5,6, Urine	No Alternate Tests Available